37

Shares

News site default image

FDA and CMS Collaboration to Improve Availability of Treatments in Practice

Shared by Radhika Narayanan | 0 34 3 | about 1 year ago

efore a medical product can be widely used in the United States, it generally must first be approved or cleared for marketing by the US Food and Drug Administration (FDA). Then, payers such as the Centers for Medicare & Medicaid Services (CMS) must decide whether the product merits coverage and payment. Because the statutes governing these agencies evolved to meet the exigencies of particular moments in the history of medical product development, the degree of convergence in standards and in the underlying evidence needed to support regulatory and payment decisions is not always immediately obvious. The resulting fragmentation—perceived or real—has led to questions about whether FDA approval or clearance for marketing will necessarily result in approval for coverage and payment.

Read More On jamanetwork.com

Categories FDA Medtech & Devices

Related Post

Links

http://jamanetwork.com/journals/jama/fullarticle/2580955
http://jamanetwork.stfi.re/journals/jama/fullarticle/2580955?sf=yowkdrg
http://stfi.re/yowkdrg
http://bit.ly/2fxLsoG

0 Votes

You must log in to post a comment

0 Comments